Tamibarotene
Tamibarotene is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against retinoic acid receptor alpha. In addition, it is known to target retinoic acid receptor gamma and retinoic acid receptor beta.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | D46 | — | 1 | 1 | — | — | 2 | |
| Tropical spastic paraparesis | D015493 | EFO_0007527 | G04.1 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Promyelocytic leukemia acute | D015473 | C92.4 | 1 | 1 | — | — | — | 2 | |
| Myeloid leukemia acute | D015470 | C92.0 | — | 2 | — | — | — | 2 | |
| Non-small-cell lung carcinoma | D002289 | — | 1 | — | — | — | 1 | ||
| Lupus nephritis | D008181 | EFO_0005761 | — | 1 | — | — | — | 1 | |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | 1 | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TAMIBAROTENE |
| INN | tamibarotene |
| Description | Tamibarotene is a dicarboxylic acid monoamide resulting from the condensation of one of the carboxy groups of terephthalic acid with the amino group of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-amine. It has a role as an antineoplastic agent and a retinoic acid receptor alpha/beta agonist. It is a member of tetralins, a retinoid and a dicarboxylic acid monoamide. It is functionally related to a 4-carbamoylbenzoic acid and a terephthalic acid. |
| Classification | Small molecule |
| Drug class | arotinoid derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21 |
Identifiers
| PDB | 2CBR |
| CAS-ID | 94497-51-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL25202 |
| ChEBI ID | 32181 |
| PubChem CID | 108143 |
| DrugBank | DB04942 |
| UNII ID | 08V52GZ3H9 (ChemIDplus, GSRS) |
Target
Agency Approved
RARA
RARA
Organism
Homo sapiens
Gene name
RARA
Gene synonyms
NR1B1
NCBI Gene ID
Protein name
retinoic acid receptor alpha
Protein synonyms
Nuclear receptor subfamily 1 group B member 1, nucleophosmin-retinoic acid receptor alpha fusion protein NPM-RAR long form, PML-DDX5-RARA fusion, PML-DDX5-RARA fusion protein, RAR-alpha, retinoic acid receptor, alpha polypeptide
Uniprot ID
Mouse ortholog
Rara (19401)
retinoic acid receptor alpha (P11416)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 330 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more